Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Yadav, Ajay K ^a,b   Sahasrabuddhe, Anagh A ^a   Dimri, Manjari ^a   Bommi, Prashant V ^a   Sainger, Rachana ^a,c   Dimri, Goberdhan P ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF DELHI   (India)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROLINE; SERINE; BMI1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

ARTICLE; BREAST EPITHELIUM; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DELETION MUTANT; DOWN REGULATION; FIBROBLAST; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MESENCHYME CELL; PHENOTYPE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STABILITY; SENESCENCE; WILD TYPE; CELL LINE; CHEMISTRY; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HALF LIFE TIME; PHYSIOLOGY; REGULATORY SEQUENCE;

CELL LINE; EPITHELIAL-MESENCHYMAL TRANSITION; HALF-LIFE; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REGULATORY SEQUENCES, NUCLEIC ACID; REPRESSOR PROTEINS; SEQUENCE DELETION;

EID: 77953667769     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-158     Document Type: Article

References (71)

1. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 2007, 8:9-22. 10.1038/nrg1981, 17173055.
2. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009, 10:697-708.
3. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6:846-856. 10.1038/nrc1991, 17060944.
4. Martinez AM, Cavalli G. The role of polycomb group proteins in cell cycle regulation during development. Cell Cycle 2006, 5:1189-1197.
5. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65:753-763. 10.1016/0092-8674(91)90383-A, 1904009.
6. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752. 10.1016/0092-8674(91)90382-9, 1904008.
7. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL, van Lohuizen M, Colomer D, Campo E. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001, 61:2409-2412.
8. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97:3896-3901. 10.1182/blood.V97.12.3896, 11389032.
9. Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, Kajiguchi T, Seto M, Kohno A, Kitamura K, Itoh Y, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005, 82:42-47. 10.1532/IJH97.05013, 16105758.
10. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001, 84:1372-1376. 10.1054/bjoc.2001.1791, 2363629, 11355949.
11. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004, 203:217-224. 10.1016/j.canlet.2003.07.009, 14732230.
12. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503-1521. 10.1172/JCI23412, 1136989, 15931389.
13. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004, 13:383-388. 10.1016/j.breast.2004.02.010, 15454193.
14. Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH, Dimri GP, Christensen R, Han T, Park NH. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 2007, 96:126-133. 10.1038/sj.bjc.6603529, 2360223, 17179983.
15. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232. 10.1158/0008-5472.CAN-06-0094, 16778197.
16. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260. 10.1038/nature01572, 12714970.
17. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, Van Lohuizen M, Marino S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004, 428:337-341. 10.1038/nature02385, 15029199.
18. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006, 66:6063-6071. 10.1158/0008-5472.CAN-06-0054, 16778178.
19. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005, 19:1432-1437. 10.1101/gad.1299505, 1151659, 15964994.
20. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003, 425:962-967. 10.1038/nature02060, 2614897, 14574365.
21. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008,
22. Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 2005, 4:1171-1175.
23. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603. 10.1016/j.cell.2009.07.011, 19665978.
24. Datta S, Hoenerhoff MJ, Bommi P, Sainger R, Guo WJ, Dimri M, Band H, Band V, Green JE, Dimri GP. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res 2007, 67:10286-10295. 10.1158/0008-5472.CAN-07-1636, 2424172, 17974970.
25. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009, 28:3022-3032. 10.1038/onc.2009.165, 2733922, 19543317.
26. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005, 20:845-854. 10.1016/j.molcel.2005.12.002, 16359901.
27. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002, 298:1039-1043. 10.1126/science.1076997, 12351676.
28. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004, 15:57-67. 10.1016/j.molcel.2004.06.020, 15225548.
29. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, Zhang Y. Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004, 431:873-878. 10.1038/nature02985, 15386022.
30. Buchwald G, van der Stoop P, Weichenrieder O, Perrakis A, van Lohuizen M, Sixma TK. Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b. Embo J 2006, 25:2465-2474. 10.1038/sj.emboj.7601144, 1478191, 16710298.
31. Li Z, Cao R, Wang M, Myers MP, Zhang Y, Xu RM. Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J Biol Chem 2006, 281:20643-20649. 10.1074/jbc.M602461200, 16714294.
32. Alkema MJ, Wiegant J, Raap AK, Berns A, van Lohuizen M. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Genet 1993, 2:1597-1603. 10.1093/hmg/2.10.1597, 8268912.
33. Cohen KJ, Hanna JS, Prescott JE, Dang CV. Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity. Mol Cell Biol 1996, 16:5527-5535. 231552, 8816465.
34. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002, 62:4736-4745.
35. Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JJ, Van Lohuizen M, Band V, Campisi J, Dimri GP. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003, 23:389-401. 10.1128/MCB.23.1.389-401.2003, 140680, 12482990.
36. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996, 21:267-271.
37. Barnes JA, Gomes AV. Proteolytic signals in the primary structure of annexins. Mol Cell Biochem 2002, 231:1-7. 10.1023/A:1014476123120, 11952151.
38. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000, 20:2423-2435. 10.1128/MCB.20.7.2423-2435.2000, 85426, 10713166.
39. Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, Salmeron A, Allen H, Hay RT, Ben-Neriah Y, Ley SC. betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol 2003, 23:402-413. 10.1128/MCB.23.1.402-413.2003, 140687, 12482991.
40. MacKichan ML, Logeat F, Israel A. Phosphorylation of p105 PEST sequence via a redox-insensitive pathway up-regulates processing of p50 NF-kappaB. J Biol Chem 1996, 271:6084-6091. 10.1074/jbc.271.11.6084, 8626394.
41. Medintz I, Wang X, Hradek T, Michels CA. A PEST-like sequence in the N-terminal cytoplasmic domain of Saccharomyces maltose permease is required for glucose-induced proteolysis and rapid inactivation of transport activity. Biochemistry 2000, 39:4518-4526. 10.1021/bi992455a, 10758001.
42. Salmeron A, Janzen J, Soneji Y, Bump N, Kamens J, Allen H, Ley SC. Direct phosphorylation of NF-kappaB1 p105 by the IkappaB kinase complex on serine 927 is essential for signal-induced p105 proteolysis. J Biol Chem 2001, 276:22215-22222. 10.1074/jbc.M101754200, 11297557.
43. Shumway SD, Maki M, Miyamoto S. The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. J Biol Chem 1999, 274:30874-30881. 10.1074/jbc.274.43.30874, 10521480.
44. Wang N, Chen W, Linsel-Nitschke P, Martinez LO, Agerholm-Larsen B, Silver DL, Tall AR. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003, 111:99-107. 151839, 12511593.
45. Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V, Dimri GP. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 2007, 67:5083-5089. 10.1158/0008-5472.CAN-06-4368, 2386662, 17545584.
46. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995, 92:9363-9367. 10.1073/pnas.92.20.9363, 40985, 7568133.
47. Guo WJ, Datta S, Band V, Dimri GP. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 2007, 18:536-546. 10.1091/mbc.E06-05-0447, 1783768, 17151361.
48. Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, Samans B, Berwanger B, Christiansen H, Lutz W. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006, 34:1745-1754. 10.1093/nar/gkl119, 1421501, 16582100.
49. Alkema MJ, Jacobs H, van Lohuizen M, Berns A. Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene 1997, 15:899-910. 10.1038/sj.onc.1201262, 9285685.
50. Fuchs SY, Spiegelman VS, Kumar KG. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004, 23:2028-2036. 10.1038/sj.onc.1207389, 15021890.
51. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003, 426:87-91. 10.1038/nature02082, 14603323.
52. Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ, Harper JW. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003, 17:3062-3074. 10.1101/gad.1157503, 305258, 14681206.
53. Ray D, Terao Y, Nimbalkar D, Chu LH, Donzelli M, Tsutsui T, Zou X, Ghosh AK, Varga J, Draetta GF, Kiyokawa H. Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 2005, 25:3338-3347. 10.1128/MCB.25.8.3338-3347.2005, 1069597, 15798217.
54. Bhatia N, Thiyagarajan S, Elcheva I, Saleem M, Dlugosz A, Mukhtar H, Spiegelman VS. Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J Biol Chem 2006, 281:19320-19326. 10.1074/jbc.M513203200, 16651270.
55. Jiang J. Regulation of Hh/Gli signaling by dual ubiquitin pathways. Cell Cycle 2006, 5:2457-2463.
56. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007, 27:4006-4017. 10.1128/MCB.00620-06, 1900029, 17387146.
57. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314:467-471. 10.1126/science.1130276, 17053147.
58. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
59. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284. 10.1038/onc.2008.333, 2690514, 18806826.
60. Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, Escriva M, Hernandez-Munoz I, Di Croce L, Helin K, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008, 28:4772-4781. 10.1128/MCB.00323-08, 2493371, 18519590.
61. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009, 119:3626-3636. 2786794, 19884659.
62. Fan C, He L, Kapoor A, Rybak AP, De Melo J, Cutz JC, Tang D. PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer 2009, 8:98. 10.1186/1476-4598-8-98, 2777864, 19903340.
63. Chatoo W, Abdouh M, David J, Champagne MP, Ferreira J, Rodier F, Bernier G. The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci 2009, 29:529-542. 10.1523/JNEUROSCI.5303-08.2009, 2744209, 19144853.
64. Dimri GP. The search for biomarkers of aging: next stop INK4a/ARF locus. Sci Aging Knowledge Environ 2004, 2004:pe40. 10.1126/sageke.2004.44.pe40, 15525836.
65. Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, Dombkowski DM, Cheng T, DePinho RA, Sharpless NE, Scadden DT. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 2006, 443:421-426.
66. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275. 10.1016/j.cell.2006.10.003, 17055429.
67. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, Sharpless NE. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453-457. 10.1038/nature05092, 16957737.
68. Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy J, Sharpless NE, Morrison SJ. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006, 443:448-452. 10.1038/nature05091, 2586960, 16957738.
69. Dimri M, Naramura M, Duan L, Chen J, Ortega-Cava C, Chen G, Goswami R, Fernandes N, Gao Q, Dimri GP, et al. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res 2007, 67:4164-4172. 10.1158/0008-5472.CAN-06-2580, 17483327.
70. Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 2000, 20:273-285. 10.1128/MCB.20.1.273-285.2000, 85083, 10594030.
71. Dimri M, Bommi P, Sahasrabuddhe AA, Khandekar JD, Dimri GP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis 2009, 31:489-95. 10.1093/carcin/bgp305, 19969553.